Leadership

Our proven executive team brings deep, diverse cell therapy experience and is committed to developing safe, effective, and accessible NK cell therapies to patients. Artiva's Board of Directors and Advisors bring years of expertise to help us realize the full potential of NK cell therapies.

Executives Directors

Fred Aslan, M.D.

Chief Executive Officer

View Bio »

Diego Miralles, M.D.

President and Head of Research and Development

View Bio »

Subhashis Banerjee, M.D.

Chief Medical Officer

View Bio »

Jennifer Bush

Chief Operating Officer

View Bio »

Christopher Horan

Chief Technical Operations Officer

View Bio »

Benjamin Dewees

SVP, Regulatory Affairs

View Bio »

David Moriarty, Ph.D.

SVP, Clinical Operations

View Bio »

Heather Raymon, Ph.D.

SVP, Research & Early Development

View Bio »

Feng Xu

SVP, Biometrics

View Bio »

Ilias Alevizos, D.M.D., M.H.S., Ph.D.

VP, Clinical Development

View Bio »

Andrew Cronauer

VP, General Counsel & Corporate Secretary

View Bio »

Sara Mills

VP, Regulatory Affairs, CMC and AlloNK Program Lead

View Bio »

John O’Neil, CPA

VP, Finance

View Bio »

Nicholas Veomett, Ph.D.

VP, Corporate Development

View Bio »

Cliff Wallace

VP, Quality

View Bio »